BioWorld

Oct. 22, 2010

View Archived Issues

Metabolic Solutions Development Raises $23.5M in Series D Round

Genentech's Herceptin Wins U.S. OK in Stomach Cancer

Coming Monday in BioWorld Insight

Corrections & Clarifications

Other News To Note

Stock Movers

Earnings Roundup

Clinic Roundup

MacroGenics Looks to Pipeline After Teplizumab Phase III Miss

MacroGenics Inc. and partner Eli Lilly and Co.'s teplizumab failed to meet its primary efficacy endpoint in a Phase III trial for Type 1 diabetes. (BioWorld Today) Read More

Adverse Event Halts Cardiome's Confirmatory Kynapid AF Trial

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...